MTSR
Metsera, Inc.
1W: -15.2%
1M: +33.4%
3M: +117.7%
$70.50
Last traded 2025-11-14 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$7.4B
52W Range12.3-83.8599
Volume27,874,411
Avg Volume3,501,952
Beta1.70
Dividend—
Analyst Ratings
Company Info
CEOChristopher Whitten Bernard
Employees93
SectorHealthcare
IndustryBiotechnology
IPO Date2025-01-31
Websitemetsera.com
3 World Trade Center
New York City, NY 10007
US
New York City, NY 10007
US
212 784 6595
About Metsera, Inc.
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| FMR LLC | J-Other | 2,230,450 | $0.00 | 2025-11-13 |
| ARCH Venture Partner | D-Return | 8,313,680 | $0.00 | 2025-11-13 |
| Marso Steven | A-Award | 17,000 | — | 2025-11-13 |
| Marso Steven | D-Return | 17,000 | $0.00 | 2025-11-13 |
| Marso Steven | D-Return | 120,000 | $29.25 | 2025-11-13 |